| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Answers for
more patients
Comprehensive diagnostic, prognostic, and predictive testing
Oncology testing is rapidly advancing — from new technology and discoveries in molecular biomarkers to emerging therapies. Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.
Guiding treatment selection
Lung cancer treatment options are selected based on
molecular test results, and proper treatment selection directly impacts patient outcomes. Selecting the most appropriate treatment — whether standard, off-label, or clinical trials — begins with high-quality molecular testing.
Providing results for more patients
Accurate results are the first step to timely, effective, and efficient patient care. Unlike other laboratories, our specimen requirements are optimized to conserve tissue, which makes results available for more patients.
Interpretation by Mayo Clinic experts
Your results are interpreted by Mayo Clinic physicians with
expertise in pulmonary oncology. Each report integrates
patient information with supporting references. This provides
patient-specific context and a better understanding of the
treatment path ahead.
Additional resources
In this month’s “Hot Topic,” Anja Roden, M.D., discusses new entities and changes of terminology in the 2021 World Health Organization (WHO) classification of lung tumors as well as the nomenclature in small biopsies.
In this month’s “Hot Topic,” Anja Roden, M.D., will discuss the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in Non-Small Cell Lung Carcinoma (NSCLC).
In this month’s “Hot Topic,” Anja Roden, M.D., discusses mesothelial proliferations, their challenges, and which ancillary testing might help to overcome some of those challenges.
Kevin Halling, M.D., gives an overview of the lung cancer NGS panel available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Oncology testing is rapidly advancing—from new technology and discoveries in molecular biomarkers to emerging therapies. Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.